You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 4, 2024

Details for Patent: 10,905,694


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,905,694 protect, and when does it expire?

Patent 10,905,694 protects JYNARQUE and SAMSCA and is included in two NDAs.

This patent has thirty patent family members in twenty-four countries.

Summary for Patent: 10,905,694
Title:Pharmaceutical solid preparation comprising benzazepines and production method thereof
Abstract: The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-t- etrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 .mu.m, and a 90% cumulative particle diameter of 100 to 200 .mu.m.
Inventor(s): Nakagawa; Shinsuke (Osaka, JP), Suzuki; Kai (Osaka, JP), Mukai; Tadashi (Osaka, JP)
Assignee: OTSUKA PHARMACEUTICAL CO., LTD. (Tokyo, JP)
Application Number:12/665,642
Patent Claim Types:
see list of patent claims
Formulation; Dosage form;

Drugs Protected by US Patent 10,905,694

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-001 Apr 23, 2018 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-002 Apr 23, 2018 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-003 Apr 23, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-004 Apr 23, 2018 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Otsuka JYNARQUE tolvaptan TABLET;ORAL 204441-005 Apr 23, 2018 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,905,694

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-163551Jun 21, 2007
PCT Information
PCT FiledJune 20, 2008PCT Application Number:PCT/JP2008/061686
PCT Publication Date:December 24, 2008PCT Publication Number: WO2008/156217

International Family Members for US Patent 10,905,694

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 067077 ⤷  Try a Trial
Austria E489944 ⤷  Try a Trial
Australia 2008264445 ⤷  Try a Trial
Brazil PI0813100 ⤷  Try a Trial
Canada 2689467 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.